Where and how are we going? Simplifying the definitive diagnosis of primary aldosteronism.

Nishikawa, Tetsuo; Nakai, Kazuki; Tsurutani, Yuya; Matsuzawa, Yoko; Saito, Jun; Omura, Masao

Nishikawa, Tetsuo; Nakai, Kazuki; Tsurutani, Yuya; Matsuzawa, Yoko; Saito, Jun; Omura, Masao.

Affiliation

Nishikawa T; Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan. tetsuon@yokohamah.johas.go.jp.
Nakai K; Nishikawa Clinic, Yokohama, Japan. tetsuon@yokohamah.johas.go.jp.
Tsurutani Y; Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
Matsuzawa Y; Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
Saito J; Endocrinology & Diabetes Center, Yokohama Rosai Hospital, Yokohama, Japan.
Omura M; Matsuzawa Clinic, Yokohama, Japan.

Hypertens Res ; 47(6): 1735-1737, 2024 Jun.

Article de En | MEDLINE | ID: mdl-38584160

Sujet(s)
Mots clés

Chemiluminescent enzyme immunoassay; Liquid chromatography-mass spectrometry/mass spectrometry; Plasma aldosterone concentration; Primary aldosteronism; Radioimmunoassay

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Hyperaldostéronisme Limites: Humans Langue: En Journal: Hypertens Res Sujet du journal: ANGIOLOGIA Année: 2024 Type de document: Article Pays d'affiliation: Japon

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google